 |
|
|
| |
MAGELLAN-1, PART 2: GLECAPREVIR/PIBRENTASVIR FOR 12 OR 16 WEEKS IN PATIENTS WITH CHRONIC HCV GENOTYPE 1 OR 4 AND PRIOR DIRECT-ACTING ANTIVIRAL TREATMENT FAILURE
|
| |
| |
Reported by Jules Levin
EASL 2017
The International Liver Congress (EASL) ⋅ Amsterdam, The Netherlands ⋅ 22 April 2017
Fred Poordad1, Stanislas Pol2, Armen Asatryan3, Maria Buti4, David Shaw5, Christophe Hézode6, Franco Felizarta7, Stuart C Gordon8, Stephen Pianko9, Michael W Fried10, David E Bernstein11, Joel Gallant12, Chih-Wei Lin3, Yang Lei3, Teresa I Ng3, Tami Pilot-Matias3, Jens Kort3, Federico Mensa3
|
| |
|
|
|
|
|
